ReviewCannabinoids: a real prospect for pain relief
Introduction
Painful stimuli are detected and encoded by primary afferent nociceptors, which relay noxious information to the spinal cord and the brain. The main ascending pain pathways are the spinothalamic and spinoparabrachial pathways, which subserve spatial discriminatory and emotional aspects of pain processing, respectively. The pharmacological management of pain, in particular chronic pain, can target peripheral nerves, spinal cord or the brain. Indeed, the mainstay analgesic morphine produces analgesia by acting at many different levels of the nociceptive pathway.
Endogenous cannabinoid mechanisms also exist at various levels in the pain pathway, in a system that is distinct from, but parallel to, that involving opiates. Cannabis was widely used in the 19th century for pain relief and there is renewed interest in cannabis-based medicines, with pain as one of the key therapeutic targets [1].
The discovery of the endogenous cannabinoid system, the availability of potent cannabinoid receptor antagonist drugs and receptor knockout mice has facilitated recent research progress on this topic. This review summarises current understanding of the involvement of the cannabinoid system in pain sensation and discusses the evidence that cannabinoid receptor ligands could be useful therapeutic agents for pain control.
Section snippets
Cannabinoid receptor localisation
Two types of cannabinoid receptors have been identified; cannabinoid CB1 receptors are located mostly in the central nervous system but are also expressed by peripheral neurones, and CB2 receptors are predominantly confined to the periphery. Both are seven-transmembrane receptors coupled to Gi/o proteins.
Cannabinoid CB1 receptors are located at many of the sites associated with peripheral and central processing of nociceptive messages. In situ hybridisation studies suggest that medium and
Pharmacological evidence from animal studies that cannabinoids are antinociceptive
Systemically administered cannabinoid agonists have demonstrable antinociceptive and antihyperalgesic effects in behavioural 6•., 7••., 8., 9., 10., 11. and electrophysiological 12., 13., 14. studies of acute and inflammatory nociception. The sites of action of cannabinoids have been extensively studied; antinociceptive effects of cannabinoids have been widely reported following peripheral, spinal and intracerebroventricular (i.c.v.) administration of different classes of cannabinoid receptor
Evidence from studies with knockout animals
Mice with a disrubted CB1 receptor gene have been generated; these CB1 receptor knockout mice have an increased mortality rate, reduced locomotor activity, increased catalepsy and hypoalgesia [40]. Results obtained with CB1 receptor knockout mice suggest that this receptor does not account for all the biological actions of anandamide. In particular, although the antinociceptive actions of Δ9-THC are virtually absent in such animals, anandamide continued to show analgesic activity in the
Interactions between endogenous cannabinoids and the vanilloid receptor
Given the evidence from knockout studies, there appear to be alternative receptors at which anandamide can act. A prime candidate is the vanilloid VR1 receptor [45••], which mediates pain responses to noxious heat or changes in pH and can be activated by exogenous application of capsaicin, the hot component of chilli peppers. Although anandamide has an affinity for the VR1 receptor in vitro that is 5-fold to 20-fold lower than its affinity for the CB1 receptor, Di Marzo et al. [45••] argue that
Conclusions and future directions
Basic research into the role of cannabinoids in pain mechanisms is progressing rapidly. The emerging concept is that the cannabinoid signalling system functions as a parallel but distinct mechanism from the opioids in modulating pain responses [53••]. Clinical progress, however, has been much slower. In the UK, the Medical Research Council has sponsored a large-scale controlled clinical trial of cannabis extract (oral) versus Δ9-THC or placebo (oral) in postoperative pain (House of Lords Report
Update
Recent work has demonstrated peripheral CB2 receptor mediated antinociception in the rat [60]. Peripheral injection of AM121, a CB2 receptor agonist, produced antinociception to thermal stimuli but did not produce the central cannabinoid effects of hypothermia, catalepsy or inhibition of locomotor activity. The authors suggest that CB2 receptor agonists may be clinically effective analgesics in the absence of central cannabinoid side effects.
Acknowledgements
The authors thank Steve Alexander and Dave Kendall for their helpful discussion.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
References (60)
- et al.
Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study
Neuroscience
(1999) - et al.
Cannabinoid receptors undergo axonal flow in sensory nerves
Neuroscience
(1999) - et al.
Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons
Neuroscience
(2000) - et al.
Cannabinoid CB1 receptor expression in rat spinal cord
Mol Cell Neurosci
(2000) - et al.
The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain
Pain
(2001) - et al.
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
Pain
(1998) - et al.
The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats
Pain
(1999) - et al.
Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2
Life Sci
(1995) Cannabinoid receptors and pain
Prog Neurobiol
(2001)- et al.
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
Pain
(1998)
Spinal mechanisms of Δ9-tetrahydrocannabinol-induced analgesia
Brain Res
Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2
Neurosci Lett
Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception
Eur J Pharmacol
Antihyperalgesic effects of spinal cannabinoids
Eur J Pharmacol
Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections
Brain Res
Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity
Brain Res
Pharmacological evaluation of aerosolized cannabinoids in mice
Eur J Pharmacol
Spinal cannabinoids are anti-allodynic in rats with persistent inflammation
Pain
The analgesic effects of R(+)-WIN55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain
Neurosci Lett
Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus
Neuroscience
Anandamide: some like it hot
Trends Pharmacol Sci
The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism
J Biol Chem
Overlap between the ligand recogition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity
FEBS Lett
Two distinctive antinociceptive systems in rats with pathological pain
Neurosci Lett
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
Biochem Pharmacol
Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder
Anesthesiology
Spinal and supraspinal components of cannabinoid-induced antinociception
J Pharm Exp Ther
An analgesic circuit activated by cannabinoids
Nature
Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat
J Neurophysiol
Cited by (149)
Maladaptive reorganization following SCI: The role of body representation and multisensory integration
2022, Progress in NeurobiologyNovel treatments for chronic pain: moving beyond opioids
2021, Translational ResearchCitation Excerpt :A number of non-opioid treatment approaches and clinically relevant targets were not covered in this review, but we feel they deserve mention here. First, the cannabinoid (CB) receptors, which belong to the GPCR superfamily, have garnered significant attention as potential targets for analgesic drug discovery.216,217 The CB1 receptor exhibits elevated expression in tissues involved in pain processing (thalamus and amygdala) and has been shown to exhibit anti-nociceptive and anti-hyperalgesia effects in chronic pain models.218,219
5.15 - The Brainstem and Nociceptive Modulation
2020, The Senses: A Comprehensive Reference: Volume 1-7, Second EditionBetacaryophyllene – A phytocannabinoid as potential therapeutic modality for human sepsis?
2018, Medical HypothesesPotent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
2023, Journal of Headache and Pain